These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 10590284

  • 1. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria.
    Andrews JM, Ashby JP, Jevons GM, Wise R.
    J Antimicrob Chemother; 1999 Dec; 44(6):819-22. PubMed ID: 10590284
    [Abstract] [Full Text] [Related]

  • 2. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
    Soussy CJ, Nguyen J, Goldstein F, Dabernat H, Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P.
    Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
    [Abstract] [Full Text] [Related]

  • 3. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
    Barry AL, Fuchs PC, Brown SD.
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
    [Abstract] [Full Text] [Related]

  • 4. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
    Aktaş Z, Gönüllü N, Salcioğlu M, Bal C, Anğ O.
    Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
    [Abstract] [Full Text] [Related]

  • 5. BSAC standardized disc susceptibility testing method (version 7).
    Andrews JM, BSAC Working Party on Susceptibility Testing.
    J Antimicrob Chemother; 2008 Aug; 62(2):256-78. PubMed ID: 18474513
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
    Piddock LJ, Jin YF.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of moxifloxacin against local bacterial isolates.
    Ling ML, Tan PL.
    Ann Acad Med Singap; 2001 Nov; 30(6):607-10. PubMed ID: 11817288
    [Abstract] [Full Text] [Related]

  • 8. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH.
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [Abstract] [Full Text] [Related]

  • 9. Calculation of composite recovery time: a new pharmacodynamic parameter.
    MacKenzie FM, Milne KE, Gould IM.
    J Antimicrob Chemother; 2002 Aug; 50(2):281-4. PubMed ID: 12161413
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N.
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [Abstract] [Full Text] [Related]

  • 11. Bactericidal properties of moxifloxacin and post-antibiotic effect.
    Boswell FJ, Andrews JM, Wise R, Dalhoff A.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():43-9. PubMed ID: 10382875
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
    Hoogkamp-Korstanje JA, Roelofs-Willemse J.
    J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT.
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [Abstract] [Full Text] [Related]

  • 14. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
    Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo MR.
    J Chemother; 2004 Feb; 16(1):30-7. PubMed ID: 15077996
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.
    Boswell FJ, Andrews JM, Wise R.
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1377-9. PubMed ID: 9174203
    [Abstract] [Full Text] [Related]

  • 16. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
    Dorai-John T, Thomson CJ, Amyes SG.
    J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
    [Abstract] [Full Text] [Related]

  • 17. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.
    Liebowitz LD, Slabbert M, Huisamen A.
    J Clin Pathol; 2003 May; 56(5):344-7. PubMed ID: 12719453
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.
    Fuchs PC, Barry AL, Brown SD.
    Diagn Microbiol Infect Dis; 2000 Dec; 38(4):243-53. PubMed ID: 11146251
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of moxifloxacin(BAY 12-8039) against respiratory tract pathogens from six Latin-American countries.
    Cardeñosa G O, Soto-Hernández JL.
    Chemotherapy; 2000 Dec; 46(6):379-82. PubMed ID: 11053902
    [Abstract] [Full Text] [Related]

  • 20. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A, Thomson KS, Moland ES, Chartrand SA, Sanders CC.
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.